-

SILVERBOW RESOURCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SilverBow Resources, Inc. - SBOW

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SilverBow Resources, Inc. (NYSE: SBOW) to Crescent Energy Company (NYSE: CRGY). Under the terms of the proposed transaction, shareholders of SilverBow will receive 3.125 shares of Crescent Class A common stock for each share of SilverBow, with the option to elect to receive all or a portion of the proceeds in cash at a value of $38 per share (subject to possible pro ration with a maximum total cash consideration for the transaction of $400 million). KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-sbow/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Managing Partner
Lewis S. Kahn
lewis.kahn@ksfcounsel.com
855-768-1857

Kahn Swick & Foti, LLC

NYSE:SBOW

Release Versions

Contacts

Kahn Swick & Foti, LLC
Managing Partner
Lewis S. Kahn
lewis.kahn@ksfcounsel.com
855-768-1857

More News From Kahn Swick & Foti, LLC

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of...

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contin...

McCormick & Co Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of McCormick & Company, Incorporated - MKC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of McCormick & Company, Incorporated (NYSE: MKC) and Unilever PLC’s (NYSE: UL) Foods business (excluding India and other excluded businesses). Under the terms of the merger agreement, upon closing of the proposed transaction, McCormick shareholders will own 35.0% of the combined company. KSF is seeking to d...
Back to Newsroom